Cell and gene therapy (CGT) is poised to revolutionize medicine, offering potential cures and transformative treatments for cancer, rare diseases, and genetic disorders. The global CGT market was valued at about $36.5B in 2025 and is projected to grow to over $183B by 2035, fueled by new FDA decisions in the first half of 2026 along with strategic partnerships between startups and big pharma to scale manufacturing and commercialization.